Bill Gates knows what's up

Bill Gates is in charge of curating this year's breakthrough technologies list put out by the MIT Technology Review, and he sees some interesting things on the horizon. Jason Stutman examines five of these and some investments to watch... You are receiving this email because you subscribed to Energy and Capital. [Click here]( to manage your e-mail preferences. [Energy and Capital logo] Bill Gates knows what's up By Jason Stutman Written Mar. 10, 2019 Every year since 2001, MIT Technology Review has released an annual list of its top 10 breakthrough technologies that will shape the way we work and live for years to come. For nearly two decades, the publication’s editorial team has curated its breakthrough technologies list on its own, but this year MIT Technology Review is leaving that job up to none other than the tech industry legend and one of the world’s richest men (soon to be first when Bezos gets divorced), Bill Gates. Every year, I look forward to this list as an investor because it gives me added inspiration on where to seek out new moneymaking opportunities. Sure, some of the technologies may be far out, but others represent practical investment opportunities for the near to mid term. With Bill Gates taking over curation this year, I’ve taken a particularly strong interest in MIT Technology Review’s annual breakthrough technology list. That said, I wanted to dedicate this week and next to parsing out his picks and the relevant investment opportunities that surround them. Of course, not all of these technologies will have actionable investments, but that’s part of the reason we’ll be expanding on each one: to separate the practical from the impractical. That all said, here’s the first half of our “investor’s take” on Bill Gates’ top 10 technology breakthroughs for 2019. Bank 1,000% on the Death of Comcast America’s most hated cable company is standing on its last leg. And it’s not because of terrible customer service or mediocre products. It’s because of a technological shift that’s scheduled to start in late-2018. It's a shift that could earn you 1,000% gains as three companies bring down big cable. [Click here for their ticker symbols.]( Technology Breakthrough #1: Robot Dexterity It’s not at all a surprise to see robotics at the top of Bill Gates’ breakthrough technology list. After all, I kicked off my investment newsletter Technology and Opportunity five years ago with something I called “Bill Gates’ Big Bet,” and that bet was on the proliferation of robots. Gates had made some very bullish remarks on the robotics industry around that time, and we highlighted numerous robotics companies that investors should be looking out for. Fast-forward to today, and we’re still incredibly bullish on robotics, as is Gates. We currently have three open robotics positions in our portfolio, and all of them are winners, with 103.8%, 57.8%, and 68.7% returns. But Gates’ remarks on robot dexterity this year are a little more specific than they’ve been in the past, with a focus on precision. As it pertains to robot dexterity, investors will want to continue betting not only on industrial robotics companies, but also on the companies producing precision-enabling sensors as well. Technology Breakthrough #2: New-Wave Nuclear Power Gates is bullish on advanced fusion and fission reactors, which isn’t surprising considering the man’s admirable push to reduce carbon emissions (without pigeonholing himself to wind and solar). Today, somewhere in the ballpark of 65% of our carbon-free power comes from nuclear, so it makes sense that Gates sees nuclear as a critical energy source of the future. Today, virtually every nuclear plant in the U.S. is a light-water reactor (LWR), based on technology invented in the 1960s. The next generation of nuclear reactors, though, is approaching, with the promise of safer and cheaper power and less nuclear waste. More specifically, we’re talking about small modular reactors (near to mid term) and advanced reactors (mid to long term). Both offer promising alternatives to LWRs, but as it stands today, the U.S. market is not quite ripe for investment yet. The Alvin W. Vogtle Electric Generating Plant in Georgia remains the only nuclear power reactor currently under construction in the U.S., and it has been plagued with cost hikes. That said, globally, there are currently over 80 advanced nuclear reactor projects under development in 20 countries outside of North America. China is a dominant force in that regard, and its utility companies, including Huaneng Power International, Inc. (NYSE: HNP), are likely the best bet on nuclear power investing right now. Technology Breakthrough #3: Predicting Preemies Gates believes that blood tests will soon be able to predict, with a high degree of accuracy, if a pregnant woman is at risk of a premature birth, saving countless lives in the process. Today, there is already something called a bilirubin blood test that can be used to predict risk of jaundice, which can lead to premature birth. Bilirubin tests, though, have been around for years, so Gates is referring to something else. Specifically, Gates is referring to a recent study (funded by his foundation) that showed you can predict a woman’s due date within a two-week window from a blood test. The test, developed by Stephen Quake, a professor of bioengineering and applied physics at Stanford University, works by looking at how RNA in a mother’s blood changes over the course of her pregnancy. As Gates admits, however, we’re still years away from such a test becoming routine or commercialized. As far as I can tell, there are no investment opportunities for this innovation quite yet, as the patent application is assigned to Leland Stanford Junior University, with no licensing deals we are aware of. [psm-cannabis-text-ad]( Technology Breakthrough #4: Gut Probe in a Pill In what sounds like something from the world of science fiction, Gates imagines a small, swallowable device that can image the gut without anesthesia. Exactly what pill Gates is referring to isn’t entirely clear, but we at least know that it ties into Gates’ ongoing fascinations with gut health, specifically the workings of the microbiome. For the uninitiated, the microbiome is effectively the ecological makeup of bacteria and viruses in our digestive tracts. Gates and others believe we’re on the verge of incredible advancements relating to the microbiome that will change the way we think about and deal with nutrition. Synthetic Biologics, Inc. (NYSE MKT: SYN) is one among a few companies focused on developing therapeutics designed to manipulate the microbiome for patient benefit. Shareholders, though, have been punished on that one over the last few years, the most recent catalyst being a devastating 1 for 35 reverse split. Technology Breakthrough #5: Custom Cancer Vaccines Bill Gates believes that custom cancer vaccines, also known as personalized vaccines for immunotherapy, could have a huge impact on the oncology market, and we certainly agree. In short, this technology works by activating a person’s immune system and training it to target cancers by their unique mutations. Unlike typical vaccines, though, these treatments would not be taken as a preventative measure but would instead be taken after being diagnosed. In 2017, early clinical trials first began showing promise of custom cancer vaccines, fending off tumors in a handful of patients. Today, the biotech industry is on the verge of commercializing the first of those treatments as companies race to be first to market. San Francisco-based Genentech, for instance, a subsidiary of Swiss pharmaceutical giant Roche (OTC: RHHBY), is working with German company BioNTech to develop personalized vaccines for cancer patients. Moderna, Inc. (NASDAQ: MRNA) is also working on its own personalized cancer vaccine. While these cancer vaccines offer hope for the oncology market, though, there is a caveat. Because the vaccines are patient specific, they cannot be manufactured in bulk. That means there are still uncertainties regarding the scalability of such treatments. Ultimately, the scalability of these medicines will rely largely on cheap genetic sequencing needed for their creation. Illumina, Inc. (NASDAQ: ILMN) is easily the top player in that regard. Until next time, [JS Sig] Jason Stutman [follow basic]( [@JasonStutman on Twitter]( Jason Stutman is Wealth Daily's senior technology analyst and editor of investment advisory newsletters Technology and Opportunity and The Cutting Edge. His strategy for building winning portfolios is simple: Buy the disruptor, sell the disrupted. Covering the broad sector of technology and occasionally dabbling in the political sphere, Jason has written hundreds of articles spanning topics from consumer electronics and development stage biotechnology to political forecasting and social commentary. Outside the office Jason is a lover of science fiction and the outdoors, and an amateur squash player at best. He writes through the lens of a futurist, free market advocate, and fiscal conservative. Jason currently hails from Baltimore, Maryland, with roots in the great state of New York. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [The First Nuclear Reactor Since the 1970s]( [A Tidal Wave of Oil Is Coming]( [Investing in New Jersey Pot Stocks]( [The Seer Sees a Natural Gas Boom]( [Natural Gas 2.0]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2019, [Angel Publishing LLC](. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.